Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
FREEHOLD, NJ, Feb. 16, 2018 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k)...
-
TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing a treatment for patients with endotoxemic septic shock, today announced that Health Canada...
-
TORONTO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing a treatment for patients with endotoxemic septic shock, today announced that Richard...
-
CYPRESS, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Mitsubishi Electric US, Inc. will present a hands-on mini lab showcasing its high-efficiency, wide-band GaN Doherty Amplifier at Radio Wireless...
-
TORONTO, ONTARIO--(Marketwired - Dec. 18, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion...
-
FREEHOLD, NJ, Dec. 14, 2017 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared...
-
TORONTO, ONTARIO--(Marketwired - Dec. 13, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion...
-
Freehold, NJ , Dec. 08, 2017 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared...
-
TORONTO, ONTARIO--(Marketwired - Nov. 14, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today...
-
TORONTO, ONTARIO--(Marketwired - Oct. 31, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today...